Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc. (Nasdaq: ENSC) is a pharmaceutical company focused on abuse-deterrent and abuse-resistant drug formulations, operating in the specialty pharmaceuticals sector. The company became publicly traded in June 2021 through its merger with Leisure Acquisition Corp, a blank-check vehicle that completed its IPO in 2019 and was sponsored by affiliates of Leisure Acquisition Corp's management team. The company filed an 8-K with the SEC on November 21, 2024, continuing its public reporting obligations under Nasdaq listing requirements. As of late 2024, Ensysce remained an active reporting company navigating the post-merger public markets environment typical of many de-SPAC biotechnology issuers. For full filing history, deal terms, sponsor details, and real-time SPAC data on Ensysce and thousands of other transactions, sign up for a SpacDesk account at spacdesk.com.